GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » 5-Year Yield-on-Cost %

Cassava Sciences (Cassava Sciences) 5-Year Yield-on-Cost % : 0.00 (As of May. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences 5-Year Yield-on-Cost %?

Cassava Sciences's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Cassava Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:



SAVA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Cassava Sciences's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Cassava Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's 5-Year Yield-on-Cost % falls into.



Cassava Sciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cassava Sciences is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Cassava Sciences  (NAS:SAVA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cassava Sciences 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (Cassava Sciences) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
Sanford Robertson director ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook officer: SVP & General Counsel 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec officer: Chief Clinical Dev. Officer 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen officer: Chief Financial Officer 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J director
Robert Z Gussin director
Scannon Patrick J Md Phd director C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p. 10 percent owner 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174